Pediatrix Medical Group, Inc. — FY 2023 Form 10-K
Reporting period: Year ended December 31, 2023; comparisons are primarily with FY 2022. This is an annual filing, not a standalone fourth-quarter report.
Business context
Pediatrix provides neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty physician services across 37 states. At year-end, it had approximately 2,620 affiliated physicians. Neonatology and other pediatric subspecialties generated 80% of net patient service revenue; maternal-fetal medicine 16%; pediatric cardiology 4%.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net revenue | $1.995 billion | $1.972 billion |
| Operating income and margin | $7.3 million; 0.4% | $172.7 million; 8.8% |
| Net income (loss) attributable to Pediatrix | ($60.4 million) | $66.3 million |
| Diluted EPS | ($0.73) | $0.79 |
| Adjusted EBITDA from continuing operations | $200.4 million | $241.0 million |
| Adjusted EPS from continuing operations | $1.26 | $1.66 |
| Operating cash flow from continuing operations | $146.1 million | $182.3 million |
Revenue grew 1.1%. Same-unit revenue increased 1.9%, reflecting a 2.0% increase from reimbursement-related factors, partly offset by a 0.1% decline in patient service volumes. Management attributed the reimbursement improvement partly to stronger collections compared with prior-year revenue-cycle performance. Practice salaries and benefits rose 4.7% to $1.45 billion; general and administrative expense declined 1.7% to $227.5 million.
Reported operating results included a $148.3 million non-cash goodwill impairment charge and a separate $20.0 million impairment of a cost-method investment. Excluding goodwill impairment and restructuring costs, operating income was $157.9 million and margin was 7.9%, versus $200.0 million and 10.1% in 2022. These are company-presented adjusted comparisons, not GAAP results.
At December 31, 2023, cash and cash equivalents were $73.3 million, short-term investments $104.5 million and working capital $94.5 million. Principal debt was $628.1 million: $400.0 million of 5.375% senior notes due 2030 and $228.1 million under the Term A Loan. The $450.0 million revolving facility was undrawn. Interest expense was $42.1 million. The company reported compliance with its debt covenants and expects operating funds, cash and available credit to meet needs for at least the next 12 months.
Contracted managed care represented 67% of net patient service revenue, government programs 26%, other third parties 5% and private pay 2%. Hospital administrative fees contributed $275.7 million, approximately 14% of net revenue. Texas accounted for approximately 32% of revenue; the five largest states together accounted for 67%.
Changes, outlook and notable matters
- Net loss replaced prior-year net income, principally reflecting the goodwill impairment and higher operating expenses. Adjusted EBITDA fell 16.8%, primarily due to higher same-unit expenses and reduced CARES Act relief.
- Cash from continuing operations declined by $36.2 million. Days sales outstanding improved to 50.5 days from 53.1 days, which management linked to improved collections.
- In the fourth quarter, a sustained share-price decline triggered goodwill testing and the $148.3 million impairment. The impairment estimate was sensitive to the control premium; a 1% change would have changed the charge by approximately $9.0 million. The separate $20.0 million investment impairment reflected adverse developments at the investee.
- Pediatrix terminated its primary revenue-cycle management services agreement with R1 RCM effective December 15, 2023, citing failure to meet service levels. It is transitioning to a hybrid internal and third-party model. Management warns that transition problems could delay collections, increase denials or costs, and affect cash flow.
- Management provided no specific revenue or earnings guidance in the supplied filing text. It expects higher-than-historical growth in clinician compensation expense. The company acquired one pediatric urology practice in 2023.
- Principal risks include reimbursement and Medicaid changes, No Surprises Act dispute outcomes, declining birth rates, geographic concentration, clinician recruitment and retention, hospital contract renewals, regulatory and billing scrutiny, and cybersecurity and privacy risks. The company also cited uncertainty around telehealth reimbursement and post-emergency regulatory rules.
- Professional liability reserves totaled $283.3 million, including retained liabilities from previously divested businesses; $33.2 million of insurance receivables were recorded for certain covered claims. The company says pending legal matters are not expected to have a material adverse effect, but outcomes are uncertain. It did not accrue for future government audits or investigations because potential exposure could not be reasonably estimated.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor concluded controls were effective. The auditor identified valuation of patient-service receivables and related collection allowances as a critical audit matter.
Important facts for investors to verify
- Whether collections, receivables and revenue-cycle performance remain stable during the transition from R1 RCM; monitor DSO, denials and cash flow.
- Whether clinician compensation and other operating costs continue to outpace revenue growth, and how this affects adjusted and GAAP margins.
- The assumptions supporting the goodwill valuation and the status of the impaired pediatric-care investment.
- Debt levels, variable-rate exposure, covenant headroom and liquidity needs; a 1% interest-rate change was estimated to affect annual pretax income by $2.3 million.
- Developments in reimbursement rules, Medicaid coverage, No Surprises Act dispute resolution, Texas and other major-state exposure, and professional liability claims.